Abstract
Aims
Pancreatic islet amyloid deposition is a characteristic feature of type 2 diabetes mellitus (T2DM). Islet amyloid polypeptide (IAPP) is co-secreted with insulin, but its secretion profile and relationship to insulin and C-peptide in response to glucose and non-glucose stimuli has not been clearly defined.
Methods
Forty subjects (13 NGT, 12 IGT and 15 T2DM) participated in an OGTT and two-step hyperglycemic (225 and 400 mg/dl) clamp (80 min/step) followed by an IV arginine bolus. Acute insulin (AIR), C-peptide (ACPR) and IAPP (AIAR) responses during each hyperglycemic step and following arginine (AIRArg) were assessed.
Results
AIR and ACPR during both hyperglycemic steps and after arginine progressively decreased from NGT to IGT to T2DM. Fasting IAPP concentrations were higher in T2DM compared to NGT and IGT subjects. The acute IAPP0–10 was markedly decreased only in T2DM, while the acute IAPP80–90 response during the second step (80–160 min) of hyperglycemic clamp and in response to arginine was markedly impaired in both IGT and T2DM. The ratio of IAPP/C-peptide during the first (225 mg/dl) and second step (400 mg/dl), and in response to arginine, was decreased in T2DM versus both NGT and IGT (p < 0.01). The acute IAPP0–10 correlated with ACPR0–10 (r = 0.665, p < 0.001) and AIR0–10 (r = 0.543, p < 0.001).
Conclusions
Basal IAPP secretion is higher in T2DM and IGT versus NGT but is reduced in response to hyperglycemia and arginine. The IAPP/C-peptide ratio is reduced with prolonged and more severe hyperglycemia in T2DM individuals.
Clinical trial registration
NCT00845182.
Similar content being viewed by others
References
DeFronzo RA, Banerji MA, Bray GA et al (2010) Determinants of glucose tolerance in impaired glucose tolerance at baseline in the actos now for prevention of diabetes (ACT NOW) study. Diabetologia 53(3):435–445
Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA (2004) Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 47(1):31–39
Tripathy D, Carlsson M, Almgren P et al (2000) Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the botnia study. Diabetes 49(6):975–980
Tripathy D, Eriksson KF, Orho-Melander M, Fredriksson J, Ahlqvist G, Groop L (2004) Parallel manifestation of insulin resistance and beta cell decompensation is compatible with a common defect in type 2 diabetes. Diabetologia 47(5):782–793
Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB (1987) Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 84(23):8628–8632
Westermark P, Wernstedt C, O’Brien TD, Hayden DW, Johnson KH (1987) Islet amyloid in type 2 human diabetes mellitus and adult diabetic cats contains a novel putative polypeptide hormone. Am J Pathol 127(3):414–417
Larsson H, Ahren B (1995) Effects of arginine on the secretion of insulin and islet amyloid polypeptide in humans. Pancreas 11(2):201–205
Guardado-Mendoza R, Davalli AM, Chavez AO et al (2009) Pancreatic islet amyloidosis, beta-cell apoptosis, and alpha-cell proliferation are determinants of islet remodeling in type-2 diabetic baboons. Proc Natl Acad Sci USA 106(33):13992–13997
Jurgens CA, Toukatly MN, Fligner CL et al (2011) Beta-cell loss and beta-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition. Am J Pathol 178(6):2632–2640
Clark A, Saad MF, Nezzer T et al (1990) Islet amyloid polypeptide in diabetic and non-diabetic Pima Indians. Diabetologia 33(5):285–289
Rocken C, Linke RP, Saeger W (1992) Immunohistology of islet amyloid polypeptide in diabetes mellitus: semi-quantitative studies in a post-mortem series. Virchows Arch A Pathol Anat Histopathol 421(4):339–344
Sempoux C, Guiot Y, Dubois D, Moulin P, Rahier J (2001) Human type 2 diabetes: morphological evidence for abnormal beta-cell function. Diabetes 50(Suppl 1):S172–S177
Zhao HL, Lai FM, Tong PC et al (2003) Prevalence and clinicopathological characteristics of islet amyloid in chinese patients with type 2 diabetes. Diabetes 52(11):2759–2766
Butler AE, Janson J, Soeller WC, Butler PC (2003) Increased beta-cell apoptosis prevents adaptive increase in beta-cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid. Diabetes 52(9):2304–2314
Huang CJ, Lin CY, Haataja L et al (2007) High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes. Diabetes 56(8):2016–2027
Kloppel G, Lohr M, Habich K, Oberholzer M, Heitz PU (1985) Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res 4(2):110–125
Matveyenko AV, Gurlo T, Daval M, Butler AE, Butler PC (2009) Successful versus failed adaptation to high-fat diet-induced insulin resistance: the role of IAPP-induced beta-cell endoplasmic reticulum stress. Diabetes 58(4):906–916
Mirzabeckov TALM, Kagan BL (1996) Pore formation by the cytotoxic islet amyloid polypeptide amylin. J Biol Chem 271:1988–1992
Ritzel RA, Meier JJ, Lin CY, Veldhuis JD, Butler PC (2007) Human islet amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and impair insulin secretion in isolated human islets. Diabetes 56(1):65–71
Haataja L, Gurlo T, Huang CJ, Butler PC (2008) Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocr Rev 29(3):303–316
Enoki S, Mitsukawa T, Takemura J et al (1992) Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 15(1):97–102
Kahn SE, Verchere CB, Andrikopoulos S et al (1998) Reduced amylin release is a characteristic of impaired glucose tolerance and type 2 diabetes in Japanese Americans. Diabetes 47(4):640–645
Sanke T, Hanabusa T, Nakano Y et al (1991) Plasma islet amyloid polypeptide (Amylin) levels and their responses to oral glucose in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 34(2):129–132
MacNamara CM, Barrow BA, Manley SE, Levy JC, Clark A, Turner RC (2000) Parallel changes of proinsulin and islet amyloid polypeptide in glucose intolerance. Diabetes Res Clin Pract 50(2):117–126
Knowles NG, Landchild MA, Fujimoto WY, Kahn SE (2002) Insulin and amylin release are both diminished in first-degree relatives of subjects with type 2 diabetes. Diabetes Care 25(2):292–297
Makimattila S, Fineman MS, Yki-Jarvinen H (2000) Deficiency of total and nonglycosylated amylin in plasma characterizes subjects with impaired glucose tolerance and type 2 diabetes. J Clin Endocrinol Metab 85(8):2822–2827
Duckworth WC, Bennett RG, Hamel FG (1998) Insulin degradation: progress and potential. Endocr Rev 19(5):608–624
Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D Jr (1984) Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest 74(4):1318–1328
Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22(9):1462–1470
Badman MK, Shennan KI, Jermany JL, Docherty K, Clark A (1996) Processing of pro-islet amyloid polypeptide (proIAPP) by the prohormone convertase PC2. FEBS Lett 378(3):227–231
Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC (2003) Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52(1):102–110
Higham CE, Hull RL, Lawrie L et al (2000) Processing of synthetic pro-islet amyloid polypeptide (proIAPP) ‘amylin’ by recombinant prohormone convertase enzymes, PC2 and PC3, in vitro. Eur J Biochem 267(16):4998–5004
Hoppener JW, Ahren B, Lips CJ (2000) Islet amyloid and type 2 diabetes mellitus. N Engl J Med 343(6):411–419
Hou X, Ling Z, Quartier E et al (1999) Prolonged exposure of pancreatic beta cells to raised glucose concentrations results in increased cellular content of islet amyloid polypeptide precursors. Diabetologia 42(2):188–194
Marzban L, Rhodes CJ, Steiner DF, Haataja L, Halban PA, Verchere CB (2006) Impaired NH2-terminal processing of human proislet amyloid polypeptide by the prohormone convertase PC2 leads to amyloid formation and cell death. Diabetes 55(8):2192–2201
Marzban L, Trigo-Gonzalez G, Zhu X et al (2004) Role of beta-cell prohormone convertase (PC)1/3 in processing of pro-islet amyloid polypeptide. Diabetes 53(1):141–148
Paulsson JF, Westermark GT (2005) Aberrant processing of human proislet amyloid polypeptide results in increased amyloid formation. Diabetes 54(7):2117–2125
Westermark P, Li ZC, Westermark GT, Leckstrom A, Steiner DF (1996) Effects of beta cell granule components on human islet amyloid polypeptide fibril formation. FEBS Lett 379(3):203–206
Hartter E, Svoboda T, Ludvik B et al (1991) Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia 34(1):52–54
Kahn SE, D’Alessio DA, Schwartz MW et al (1990) Evidence of cosecretion of islet amyloid polypeptide and insulin by beta-cells. Diabetes 39(5):634–638
Abdul-Ghani MA, Matsuda M, Jani R et al (2008) The relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose tolerance. Am J Physiol Endocrinol Metab 295(2):E401–E406
Novials A, Sarri Y, Casamitjana R, Rivera F, Gomis R (1993) Regulation of islet amyloid polypeptide in human pancreatic islets. Diabetes 42(10):1514–1519
Tura A, Ludvik B, Nolan JJ, Pacini G, Thomaseth K (2001) Insulin and C-peptide secretion and kinetics in humans: direct and model-based measurements during OGTT. Am J Physiol Endocrinol Metab 281(5):E966–E974
Clodi M, Thomaseth K, Pacini G et al (1998) Distribution and kinetics of amylin in humans. Am J Physiol 274(5 Pt 1):E903–E908
Bassi R, Fiorina P (2011) Impact of islet transplantation on diabetes complications and quality of life. Curr Diabetes Rep 11(5):355–363
Fiorina P, Vergani A, Petrelli A et al (2008) Metabolic and immunological features of the failing islet-transplanted patient. Diabetes Care 31(3):436–438
Polastri L, Galbiati F, Bertuzzi F et al (2002) Secretory defects induced by immunosuppressive agents on human pancreatic beta-cells. Acta Diabetol 39(4):229–233
Vergani A, Fotino C, D’Addio F et al (2013) Effect of the purinergic inhibitor oxidized ATP in a model of islet allograft rejection. Diabetes 62(5):1665–1675
Acknowledgments
We thank the nurses on the Bartter Research Unit (BRU) for their diligent care of our patients and especially James King, R.N. and John Kincade RN for carrying out the hyperglycemic clamp studies. The study was supported by a research grant from Takeda Pharmaceuticals to Devjit Tripathy.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that there is no conflict of interests.
Human and animal rights disclosure
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5).
Informed consent disclosure
Informed consent was obtained from all patients for being included in the study.
Additional information
Managed by Massimo Federici.
Rights and permissions
About this article
Cite this article
Guardado-Mendoza, R., Chávez, A.O., Jiménez-Ceja, L.M. et al. Islet amyloid polypeptide response to maximal hyperglycemia and arginine is altered in impaired glucose tolerance and type 2 diabetes mellitus. Acta Diabetol 54, 53–61 (2017). https://doi.org/10.1007/s00592-016-0904-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00592-016-0904-7